Investors Purchase Large Volume of Call Options on Reviva Pharmaceuticals (NASDAQ:RVPH)

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) saw some unusual options trading on Wednesday. Stock investors acquired 3,065 call options on the stock. This represents an increase of 235% compared to the typical volume of 915 call options.

Wall Street Analysts Forecast Growth

RVPH has been the topic of several recent analyst reports. Maxim Group reiterated a “hold” rating on shares of Reviva Pharmaceuticals in a report on Friday, August 16th. EF Hutton Acquisition Co. I upgraded Reviva Pharmaceuticals to a “strong-buy” rating in a report on Monday, September 23rd. Finally, Benchmark reissued a “speculative buy” rating and set a $17.00 price target on shares of Reviva Pharmaceuticals in a research report on Monday, August 26th.

Reviva Pharmaceuticals Stock Down 1.6 %

Reviva Pharmaceuticals stock opened at $2.77 on Friday. The firm has a fifty day moving average of $1.30 and a 200-day moving average of $1.23. Reviva Pharmaceuticals has a 52-week low of $0.60 and a 52-week high of $5.67. The firm has a market capitalization of $92.63 million, a P/E ratio of -2.50 and a beta of -0.02.

Institutional Trading of Reviva Pharmaceuticals

A hedge fund recently raised its stake in Reviva Pharmaceuticals stock. Geode Capital Management LLC grew its stake in shares of Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) by 17.9% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 278,496 shares of the company’s stock after purchasing an additional 42,376 shares during the quarter. Geode Capital Management LLC owned 0.83% of Reviva Pharmaceuticals worth $401,000 at the end of the most recent quarter. Institutional investors and hedge funds own 63.18% of the company’s stock.

Reviva Pharmaceuticals Company Profile

Reviva Pharmaceuticals Holdings, Inc, a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of various neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis.